



May 29, 2018

Revance Announces Departure of Chief Financial Officer

NEWARK, Calif.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ:RVNC), a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that Lauren Silvernail has resigned as Revance's Chief Financial Officer and Chief Business Officer, effective as of May 29, 2018, to pursue a Chief Financial Officer role at an aesthetics company in Orange County, California, where she resides. Her departure is not based on any disagreement with the company's accounting principles or practices, internal controls or financial statement disclosures.

Following Ms. Silvernail's resignation, certain members of management and the Company's existing finance team will assume the duties and responsibilities of the office on an interim basis.

Revance is initiating a search for its next Chief Financial Officer, who will play an important role as the Company prepares for the commercialization of its lead product candidate, DaxibotulinumtoxinA for Injection (RT002).

About Revance Therapeutics, Inc.

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and therapeutic conditions, including muscle movement disorders and pain. The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis, with plans to initiate studies in upper limb spasticity and chronic migraine. RT002 has the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA. More information on Revance may be found at www.revance.com.

"Revance Therapeutics" and the Revance logo are registered trademarks of Revance Therapeutics, Inc.

View source version on [businesswire.com](https://www.businesswire.com/news/home/20180529005411/en/): <https://www.businesswire.com/news/home/20180529005411/en/>

INVESTORS

Revance Therapeutics, Inc.:
Jeanie Herbert, 714-325-3584
jherbert@revance.com

or
Burns McClellan, Inc.:
Ami Bavishi, 212-213-0006
abavishi@burnsmc.com

or
MEDIA
General Media:
TOGORUN:
Mariann Caprino, 917-242-1087
m.caprino@togorun.com

or
Trade Media:
Nadine Tosk, 504-453-8344
nadinepr@gmail.com

Source: Revance Therapeutics, Inc.

News Provided by Acquire Media